A case of pulmonary Mycobacterium heckeshornense infection in a healthy Japanese man

Eriko Iitoh, Masaki Tominaga*, Masaki Okamoto, Yuki Sakazaki, Masayuki Nakamura, Takashi Kinoshita, Tomotaka Kawayama, Tomoaki Hoshino

Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Fukuoka, 830-0011, Japan

A R T I C L E   I N F O
Keywords:
Mycobacterium heckeshornense
Non-tuberculous mycobacterium infection
Matrix-assisted laser desorption ionization-time of flight mass spectrometry
MALDI-TOF MS
Mycobacterium xenopi

A B S T R A C T
A 72-year-old man, healthy, smoker, with long-standing cough, was referred to our hospital and his chest X-ray (CXR) revealed a cavity lesion in the right upper lobe. Direct sputum smears, but not culture in solid medium, were positive for acid-fast bacilli (AFB) without tuberculosis DNA. The preliminary diagnosis was of a non-tuberculous infection that progressed slowly, and the CXR showed the condition to worsen daily. Four years later, a commercialized mycobacteria growth indicator tube system was used to culture the colonies of AFB successfully in liquid medium, and the species Mycobacterium heckeshornense was identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry. The patient responded well to triple therapy with rifampicin, ethambutol, and clarithromycin, the sputum cultures remained negative and the roentgenogram showed minor improvement over the following 6 months.

1. Introduction
A species of Mycobacterium (M.) heckeshornense was first described as a new isolated non-tuberculosis mycobacteria (NTM) which infects human. It was reported in a patient with pulmonary infiltrations in 2000 [1]. Except for pulmonary infectious diseases with M. heckeshornense [2–9], diseases such as spinal osteomyelitis and diskitis [10], lumbar spondyloïdïtis [11], and lymphadenitis [12] were reported as systemic diseases. M. heckeshornense might be categorized as Runyon group II, as a slow-growing scotochromogenic mycobacteria [4,13], and be misdiagnosed as M. xenopi. The pathogenesis of infection by these two bacteria is similar, but M. xenopi can be distinguished by 16S ribosomal RNA (rRNA) and 16S–23S spacer gene sequences [2,6]. Today, a matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) technique was developed to easily identify bacterial species, including the species of M. heckeshornense [8,14]. We herein report a rare case of a healthy Japanese man with pulmonary M. heckeshornense infections by using modified liquid culture system and the MALDI-TOF MS techniques. Furthermore, triple anti-mycobacterial therapy with rifampicin (RFP), ethambutol (EB), and clarithromycin (CAM) was successful for the treatment of the progressive pulmonary disease.

2. Case report
A 72-year-old healthy man with chronic cough and CXR abnormalities was referred to our clinic. He was a current smoker and his smoking index was 92 pack-years. His CXR (Fig. 1A) and computed tomography (CT) (Fig. 1B) revealed infiltrations of cavity lesions at the right upper lobe. Direct sputum smears were positive for acid-fast bacilli (AFB), although the DNAs of Mycobacterium tuberculosis (MTB) and Mycobacterium avium complex (MAC) were not detected by polymerase chain reaction (PCR) techniques (SRL co., Tokyo, Japan). AFB cultures in 2% Ogawa egg slant medium (Kyokuto, Tokyo, Japan) under standard

Abbreviations: AFB, acid-fast bacilli; CAM, clarithromycin; CT, computed tomography; CXR, chest x-ray; DDH, DNA–DNA hybridization; EB, ethambutol; M, Mycobacterium; MAC, Mycobacterium avium complex; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; MGIT, mycobacteria growth indicator tube; MIC, minimum inhibitory concentration; MTB, Mycobacterium tuberculosis; NTM, nontuberculous mycobacteria; PCR, polymerase chain reaction; RE, rifampicin plus ethambutol; RFP, rifampicin; rRNA, ribosomal RNA.

* Corresponding author. Department of Medicine 1, Division of Respirology, Neurology, and Rheumatology, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
E-mail addresses: e0r1i2i2@icloud.com (E. Iitoh), tominaga.masaki@med.kurume-u.ac.jp (M. Tominaga), okamoto.masaki@med.kurume-u.ac.jp (M. Okamoto), sakazaki.med.kurume-u.ac.jp (Y. Sakazaki), nakamura.masayuki@med.kurume-u.ac.jp (M. Nakamura), tkino@kurume-u.ac.jp (T. Kinoshita), kawayama.tomotaka@med.kurume-u.ac.jp (T. Kawayama), hoshino@med.kurume-u.ac.jp (T. Hoshino).
https://doi.org/10.1016/j.rmcr.2020.101093
Received 6 April 2020; Received in revised form 13 May 2020; Accepted 13 May 2020
Available online 16 May 2020
2213-0071/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
conditions showed no growth. His CXR abnormalities were diagnosed as non-tuberculosis mycobacteria infection with unknown causes. His home doctor followed up the patient, as the chronic cough was relieved with temporary cough medicines or spontaneously.

Four years later, he revisited our clinic with cough recurrence and a weight loss of 5 kg/year with 16.4 kg/m² of body mass index. His vital signs were almost normal and his body temperature was 36.7 °C. His white blood cells count was 5000 cells/µL and serum C-reactive protein level was 2.26 mg/L. His chest CT revealed worsened cavity lesions with surrounding infiltrative shadows at the right upper lobe (Fig. 1C).

Direct sputum smears were positive for AFB, although MTB and MAC-DNA could not be detected by PCR techniques and standard AFB cultures; AFB was ultimately successfully cultured in the mycobacterium growth indicator tubes (MGIT) system (BD Biosciences, Sparks, MD, USA). A species of M. heckeshornense was finally identified with the MALDI-TOF MS techniques, although no match of 18 mycobacterial species (not involving M. heckeshornense) were identified among the cultured AFB strains by the commercial kits of the DNA-DNA hybridization techniques (DDH Mycobacteria, Kyokuto, Japan). The progressive pulmonary M. heckeshornense infections were defined in the patient, because the species was isolated repeatedly from sputum samples on different days after fiberoptic bronchoscopy.

We summarized the characteristics of 11 patients (number of male, 6; median age at diagnosis, 52.6 years [range: 30–72 years]) with pulmonary M. heckeshornense infections based on our case and previous case reports [1–9] (Tables 1 and 2). Five patients were in the immunocompetent state, and the remaining 6 patients had some underlying diseases. Only two patients had no symptoms, although most patients had similar respiratory and general symptoms with other NTM infections. The number of patients diagnosed with lung M. heckeshornense infections were 7, by the 16s rRNA sequence analysis, 2 by the DNA strip assay and 2 by the MALDI-TOF MS techniques, respectively. The CXR and CT abnormalities of lung fields were limited to the right upper lobe in six patients and 6 had cavity lesions. The regimens for M. heckeshornense infections varied, although multidrug therapy was becoming widespread in Japan and was helpful for the isolation of M. heckeshornense species [8].

The indirect drug susceptibility of M. heckeshornense strain was tested according to the absolute concentration method using a microtiter technique developed by a commercial laboratory (BML, Tokyo, Japan). The minimum inhibitory concentrations (MIC) of isoniazid, RFP, EB, and streptomycin used were 0.2 g/mL, 40 g/mL, 2.5 g/mL, and 10 g/mL, respectively. According to the previous reports, M. heckeshornense was resistant to INH, but susceptible to RFP, EB, amikacin, CAM, and ciprofloxacin (1). Our case showed similar susceptibility to previous reports. Triple anti-mycobacterial therapy with RFP, EB and CAM at 450, 750, and 600 mg/day, respectively (his body weight was under 50 kg) was started against the progressive pulmonary M. heckeshornense infections based on the results of MIC and the regimens in the previous reports [1–9]. His symptoms and abnormal shadows on chest CT improved 6 months after the treatments without adverse events (Fig. 1D). Mycobacterial cultures remained negative.

3. Discussion

We experienced a rare case of pulmonary M. heckeshornense infection in a healthy Japanese man. Triple anti-mycobacterial therapy with RFP, EB, and CAM was successful for the treatment of progressive pulmonary M. heckeshornense infection. M. heckeshornense shows a very slow growth rate over 37–45 °C, and the differences in the growth temperature depends on the individual isolates of M. heckeshornense [1,3]. While we were initially unable to culture the sputum AFB on solid medium, the AFB were ultimately successfully grown using the MGIT system. According to the previous reports, isolates from 4 to 2 cases grew either in MGIT [2,5,7,8] or solid medium [3,9], respectively, while isolates from 2 additional cases grew in both conditions [3,4]. Curiously, paralleling our observation, other study reported an isolated whose culture was only achieved with MGIT, and not solid medium [5]. This is possibly because the MGIT method increased the culture-positive rate, as others reported: the culture-positive rate in smear-negative specimens was greatly increased [15]. It is possible that patients infected with M. heckeshornense have not been diagnosed correctly, because the MALDI-TOF MS techniques and 16s rRNA method are performed only in few laboratories. However, the use of MALDI-TOF MS techniques is becoming widespread in Japan and was helpful for the isolation of M. heckeshornense species [8].

The three most common NTM pathogens of lung diseases are M. gordonae (31.8%), M. abscessus (22.4%), and M. fortuitum (11.8%)
previous results of drug susceptibility in isolated initial regimen of triple therapy with RFP, EB, and CAM, by reference to nicity in basic research of MALDI-TOF MS techniques may be a useful method for identifying rare M. heckeshornense ease [13]. The DNA-DNA hybridization techniques did not cover patient met the American Thoracic Society/Infectious Diseases Society of America diagnostic criteria of nontuberculous mycobacterial lung disease [13]. The DNA-DNA hybridization techniques did not cover 
treatments in the future. However, attention should be paid to the prognosis and timing of ending treatments in the future.

In conclusion, we experienced a rare case of pulmonary M. heckeshornense infection and summarized the previous reported cases. The widespread use of MALDI-TOF MS techniques and triple therapy with RFP, EB, and CAM may contribute to early diagnosis and good controls of M. heckeshornense infections.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Declaration of competing interest**

The authors have no conflicts of interest to declare.

except for MAC and M. kansasii in Japan [16]. To our knowledge, the pulmonary M. heckeshornense infections are rare in Japan as well as worldwide (Table 1). The pathogenesis of M. heckeshornense is still unclear, although the species seems to infect both immunocompromised and immunocompetent patients [1–12].

With these clinical, radiologic, and microbiologic findings, the patient met the American Thoracic Society/Infectious Diseases Society of America diagnostic criteria of nontuberculous mycobacterial lung disease [13]. The DNA-DNA hybridization techniques did not cover M. heckeshornense in commercial kits in Japan. M. heckeshornense species could be isolated by the MALDI-TOF MS techniques in our patient. The MALDI-TOF MS techniques may be a useful method for identifying rare species of NTM, such as M. heckeshornense [8,14].

The recommended treatments have not been established for lung M. heckeshornense infections [1–13,16,17]. We carefully selected the initial regimen of triple therapy with RFP, EB, and CAM, by reference to previous results of drug susceptibility in isolated M. heckeshornense strains [1–9]. We also referred to previous therapeutic outcomes and basic research of M. xenopi infections, because of the similar pathogenicity in M. heckeshornense and M. xenopi [1,17–21]. Our selected regimen led to good responses in the patient’s respiratory and general symptoms, maintained a negative culture result, and showed improvements in CXR abnormalities over the following 6 months (Fig. 1D). However, attention should be paid to the prognosis and timing of ending treatments in the future.

Table 1

| Case no. | Report | Age | Sex | Underlying diseases | Symptoms | Specimens with identified bacilli | Radiographic findings | Location |
|----------|--------|-----|-----|---------------------|----------|-----------------------------------|-----------------------|----------|
| 1        | 2018   | 72  | Male| None                | cough and weight loss | BALF sputum | cavity with infiltrations | RUL      |
| 2        | 2000   | 30  | Male| None                | cough and fatigue | sputum   | cavity with infiltrations | BUL      |
| 3        | 2004   | 43  | Male| Pneumothorax and OMI | night sweat, weight loss and fatigue | Pleural effusion | Infections with right pleural effusion | RUL      |
| 4        | 2006   | 51  | Female| Old Tuberculosis | Hemoptysis | Sputum | Infections | BUL      |
| 5        | 2007   | 71  | Male| Pneumonia          | None       | Sputum | Cavity | RUL      |
| 6        | 2008   | 65  | Female| Post RULL due to traffic accident | Dyspnea on exertion, cough and weight loss | Sputum | Cavity and infiltrations with unknown | RUL      |
| 7        | 2011   | 68  | Male| None               | Cough and hemopterus | Sputum | Cavity and infiltrations with unknown | RUL      |
| 8        | 2015   | 47  | Male| None               | N/A       | Sputum | Consolidations | RUL      |
| 9        | 2018   | 53  | Female| Alcoholism         | Cough, fever and fatigue | Sputum | Cavity and infiltrations | BUL      |
| 10       | 2018   | 40  | Male| Behçet disease    | Cough     | BALF   | Isolated nodule | RUL      |
| 11       | 2018   | 39  | Female| None              | None      | TBLB    | Cavity and infiltrations | RUL      |

Abbreviation: OMI: old myocardial infarction; BALF: bronchoalveolar lavage; TBLB: transbronchial biopsy; RUL: right upper lobe; BUL: bilateral upper lobe.

Table 2

| Case no. | Methods of identification | Regimens of treatment | Drug susceptibility | Prognosis |
|----------|---------------------------|-----------------------|---------------------|-----------|
|          |                           |                       | INH     | RFP    | EB     | SM     | KM     | LVFX   | CPFX   | CAM    |        |
| 1        | MALDI-TOF MS              | CAM + RE              | I       | S      | S      | S      | S      | S      | S      | S      | improved |
| 2        | 16S rRNA gene sequence   | HRE/PTH/CPFX and RUL lobectomy | –      | –      | –      | –      | –      | –      | –      | –      | N/A      |
| 3        | 16S rRNA gene sequence   | HREZ + RE             | I       | S      | I      | S      | –      | –      | S      | S      | not changed |
| 4        | 16S rRNA gene sequence   | RE/KM                 | –       | –      | –      | –      | –      | –      | –      | –      | dead     |
| 5        | 16S rRNA gene sequence   | None                  | –       | –      | –      | –      | –      | –      | –      | –      | improved |
| 6        | DNA strip assay          | HREZ + OFLX + RE + CAM/MFLX | –       | S      | S      | –      | –      | –      | S      | S      | improved |
| 7        | 16S rRNA gene sequence   | HREZ + HRE            | I       | S      | S      | S      | S      | S      | S      | S      | not changed |
| 8        | 16S rRNA gene sequence   | MFLX + MFLX           | –       | –      | –      | –      | –      | –      | –      | –      | improved |
| 9        | DNA strip assay          | HREZ + HRE/LVFX/CAM   | –       | –      | –      | –      | –      | –      | –      | –      | improved |
| 10       | MALDI-TOF MS             | HRE/STFX              | –       | S      | S      | S      | S      | S      | S      | S      | improved |
| 11       | 16S rRNA gene sequence   | HREZ + RE/CAM and RUL lobectomy | –       | S      | S      | S      | S      | S      | S      | S      | improved |

Abbreviation: 16S rRNA: 16S ribosomal ribonucleic acid gene sequence; AMK: amikacin; CAM: clarithromycin; CPFX: ciprofloxacin; DNA: deoxyribonucleic acid; EB: ethambutol; HRE: isoniazid + rifampicin + ethambutol; HREZ: isoniazid + rifampicin + ethambutol + pyrazinamide; INH: isoniazid; KM: kanamycin; LVFX: levofloxacin; MALDI-TOF MS: Matrix assisted laser desorption ionization-time of flight mass spectrometry; MFLX: moxifloxacin; N/A: not available; OFLX: ofloxacin; OML: old myocardial infarction; PTH: prothionamide; RE: rifampicin + ethambutol; RFP: rifampicin; RUL: right lower lobe; SM: streptomycin; STFX: sitafloxacin; S: susceptible; I: intermediate; R: resistant.
Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.rmcr.2020.101093.

References

[1] A. Roth, U. Reischl, N. Schoenfeld, I. Neumann, S. Emmer, M. Fischer, H. Mauch, R. Loddenkemper, R.M. Kroppenstedt, Mycobacterium heckeshornense sp. nov., a new pathogenic slowly growing Mycobacterium sp. causing cavitary lung disease in an immunocompetent patient, J. Clin. Microbiol. 38 (2000) 4102–4107.
[2] P. Westenend, B. Maraha, R. van Uffelen, R. Schutte, W. de Lange, Mycobacterium heckeshornense infection in an immunocompetent patient and identification by 16S rRNA sequence analysis of culture material and a histopathology tissue specimen, J. Clin. Microbiol. 42 (2004) 4386–4389.
[3] Y. Kazumi, J. Sugawara, M. Wada, K. Kimura, H. Itono, Microbiologically identified isolates of Mycobacterium heckeshornense in two patients, Kekkaku 81 (2006) 603–607 [Japanese].
[4] F. Jaureguy, V. Ioos, P. Marzouk, M. Hornstein, B. Picard, M.C. Gutierrez, et al., Mycobacterium heckeshornense: an emerging pathogen responsible for a recurrent lung infection, J. Infect. 54 (2007) e33–e35.
[5] A. Hisamoto, S. Ozaki, M. Sakugawa, T. Komoto, A. Tamaoki, T. Miyake, et al., A possible case of pulmonary infection due to Mycobacterium heckeshornense, Nihon Kokyuki Gakkai Zasshi 46 (2008) 1019-1025 [Japanese].
[6] K. Morimoto, Y. Kazumi, S. Maeda, K. Yoshimori, T. Yoshiyama, H. Ogata, et al., Mycobacterium heckeshornense lung infection that was diagnosed as Mycobacterium xenopi disease by DNA-DNA hybridization (DDH), Intern. Med. 50 (2011) 1251–1253.
[7] C. Coitinho, G. Greif, J. van Ingen, P. Laserra, C. Robello, C. Rivas, First case of Mycobacterium heckeshornense cavitary lung disease in the Latin America and Caribbean region, New Microbes New Infect. 9 (2015) 63–65.
[8] A. Yokoyama, H. Kage, Y. Ohama, T. Sato, N. Miyashita, S. Noguchi, S. Okugawa, Y. Yamauchi, K. Moriya, T. Nagase, Mycobacterium heckeshornense lung infection diagnosed by matrixassistedlaser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), J. Infect. Chemother. 24 (2018) 763–765.
[9] F. Kurosaiki, T. Yoshimoto, M. Nakayama, M. Bando, K. Hagivara, Pulmonary Mycobacterium heckeshornense infection in a healthy woman, J. Infect. Chemother. 24 (2018) 483–486.
[10] R.J. Carpenter, P.C.F. Graf, Poit’s disease? AIDS-associated Mycobacterium heckeshornense spinal osteomyelitis and diskitis, J. Clin. Microbiol. 53 (2015) 716–718.
[11] A.A. Elyouffi, J.R.S. Leiter, M.J. Goytan, D.B. Robinson, Mycobacterium heckeshornense lumbar spondylodiskitis in a patient with rheumatoid arthritis receiving etanercept treatment, J. Rheumatol. 36 (2009) 2130–2131.
[12] S.J. McBride, S.L. Taylor, S.K. Pandey, D.J. Holland, First case of Mycobacterium heckeshornense lymphadenitis, J. Clin. Microbiol. 47 (2009) 268–270.
[13] D.E. Griffith, T. Aksamit, B.A. Brown-Elliott, A. Catanazaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huiti, M.F. Isdahmarco, M. Iseman, K. Olivier, S. Rouas, C.P. von Reys, R.J. Wallace Jr., K. Winthrop, ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175 (4) (2007) 367–416.
[14] A. Van Belkum, M. Welker, D. Pincus, J.P. Charrier, V. Girard, Matrix-assisted laser desorption ionization time-of-flight mass spectrometry in clinical microbiology: what are the current issues? Ann. Lab. Med. 37 (6) (2017) 475–483.
[15] G. Pfiffer, H.-M. Wehlsee, P. Körbling, C. Cielak, M.J. Casal, J. Gutierrez, S. Ruch-Gerdes, Comparison of the mycobacteria growth indicator tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli, J. Clin. Microbiol. 35 (1997) 364–368.
[16] A. Kurashima, Treatment of relatively rare species nontuberculous pulmonary mycobacteriosis, Kekkaku 86 (12) (2011) 923–932 [Japanese].
[17] Research Committee of the British Thoracic Society, First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol, and isoniazid versus rifampicin and ethambutol, Thorax 56 (3) (2001) 167–172.
[18] British Thoracic Society, Management of opportunistic mycobacterial infections: joint tuberculosis committee guidelines 1999. Subcommittee of the joint tuberculosis committee of the British Thoracic Society, Thorax 55 (3) (2000) 210–218.
[19] K.E. Tan, B.C. Ellis, R. Lee, P.D. Stamper, S.K. Zhang, K.C. Carroll, Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness, J. Clin. Microbiol. 50 (2012) 3301–3308.
[20] P.A. Jenkins, I.A. Campbell, Research Committee of The British Thoracic Society, Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment, Respir. Med. 97 (4) (2003) 439–444.
[21] N. Louiss, C. Truffot-Pernot, A. Bentoucha, J. Robert, B. Ji, J. Grosset, Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice, Antimicrob. Agents Chemother. 45 (11) (2001) 3229–3230.